Invasive lobular carcinoma of the breast: patient response to systemic endocrine therapy and hormone response in model systems
Invasive lobular carcinoma of the breast (ILC) represents 10–15% of all newly diagnosed
breast cancers, affecting∼ 30,000 women annually in the United States. However, ILC is
critically understudied as a breast cancer subtype. Though the vast majority of ILC are
estrogen receptor-positive and present with overall favorable biomarkers, ILC patients do
not benefit from improved outcomes versus other breast cancer patients. Patient outcomes,
in particular in response to endocrine therapies, are not well understood in ILC, due in large …
breast cancers, affecting∼ 30,000 women annually in the United States. However, ILC is
critically understudied as a breast cancer subtype. Though the vast majority of ILC are
estrogen receptor-positive and present with overall favorable biomarkers, ILC patients do
not benefit from improved outcomes versus other breast cancer patients. Patient outcomes,
in particular in response to endocrine therapies, are not well understood in ILC, due in large …